当前位置:首页 - 行情中心 - 和元生物(688238) - 财务分析 - 现金流量表

和元生物

(688238)

  

流通市值:40.39亿  总市值:40.89亿
流通股本:6.41亿   总股本:6.49亿

现金流量表

报告期2026-03-312025-12-312025-09-302025-06-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金48,630,562.32257,555,229.9184,194,824.98107,711,534.49
  收到其他与经营活动有关的现金5,750,101.7528,663,348.188,754,656.156,092,665.15
  经营活动现金流入小计54,380,664.07286,218,578.08192,949,481.13113,804,199.64
  购买商品、接受劳务支付的现金40,109,253.66143,608,557.22111,382,774.0874,993,780.65
  支付给职工以及为职工支付的现金49,882,134.21188,568,976.14145,674,984.8997,783,019.34
  支付的各项税费3,466,683.7211,675,367.158,167,745.625,524,246.52
  支付其他与经营活动有关的现金26,994,825.1944,960,622.5338,304,791.9324,002,770.72
  经营活动现金流出小计120,452,896.78388,813,523.04303,530,296.52202,303,817.23
  经营活动产生的现金流量净额-66,072,232.71-102,594,944.96-110,580,815.39-88,499,617.59
二、投资活动产生的现金流量:
  收回投资收到的现金30,000,000313,685,358.8223,685,358.8207,783,792.14
  取得投资收益收到的现金17,532.181,439,028.551,083,401.26680,175.51
  处置固定资产、无形资产和其他长期资产收回的现金净额-1,321,9101,201,0001,201,000
  收到的其他与投资活动有关的现金-34,604,082.4834,604,082.48-
  投资活动现金流入小计30,017,532.18351,050,379.83260,573,842.54209,664,967.65
  购建固定资产、无形资产和其他长期资产支付的现金31,655,989.08126,243,412.59104,909,985.590,939,935.72
  投资支付的现金81,650,000314,000,000265,000,000200,000,000
  取得子公司及其他营业单位支付的现金-116,922.06116,922.06116,922.06
  支付其他与投资活动有关的现金-21,221,013.7421,221,013.74-
  投资活动现金流出小计113,305,989.08461,581,348.39391,247,921.3291,056,857.78
  投资活动产生的现金流量净额-83,288,456.9-110,530,968.56-130,674,078.76-81,391,890.13
三、筹资活动产生的现金流量:
  吸收投资收到的现金1,650,000---
  取得借款收到的现金115,000,000280,000,000234,903,753.27200,000,000
  筹资活动现金流入小计116,650,000280,000,000234,903,753.27200,000,000
  偿还债务支付的现金118,483,500101,044,371.2686,200,50078,717,000
  分配股利、利润或偿付利息支付的现金2,434,797.598,348,247.285,907,487.573,713,506.14
  支付其他与筹资活动有关的现金74,194.17101,803,652.48101,739,001.89100,137,977.16
  筹资活动现金流出小计120,992,491.76211,196,271.02193,846,989.46182,568,483.3
  筹资活动产生的现金流量净额-4,342,491.7668,803,728.9841,056,763.8117,431,516.7
四、汇率变动对现金及现金等价物的影响-50,528.32-20,263.68-66,210.72-23,479.12
五、现金及现金等价物净增加额-153,753,709.69-144,342,448.22-200,264,341.06-152,483,470.14
  加:期初现金及现金等价物余额290,551,803.61434,894,251.83434,894,251.83434,894,251.83
  期末现金及现金等价物余额136,798,093.92290,551,803.61234,629,910.77282,410,781.69
补充资料:
  净利润--234,810,012.67--104,481,169.78
  资产减值准备-22,903,467.32-509,253.14
  固定资产和投资性房地产折旧-93,224,306.35-45,066,475
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-93,224,306.35-45,066,475
  无形资产摊销-2,086,518.97-1,013,491.86
  长期待摊费用摊销-2,720,533.56-1,360,266.78
  处置固定资产、无形资产和其他长期资产的损失-1,072,763.43-879,106.69
  公允价值变动损失--86,487.4--84,032.41
  财务费用-8,634,944.92-3,735,988.14
  投资损失--6,089,808.86-306,068.54
  递延所得税-1,598,591.27-1,636,905.43
  其中:递延所得税资产减少--1,431,170.67-1,667,041.85
    递延所得税负债增加-3,029,761.94--30,136.42
  存货的减少-1,341,469.12--3,677,137.3
  经营性应收项目的减少--33,990,586.92--20,158,514.13
  经营性应付项目的增加-33,167,175.79--15,834,876.89
  其他-1,339,323.69--
  现金的期末余额-290,551,803.61-282,410,781.69
  减:现金的期初余额-434,894,251.83-434,894,251.83
  现金及现金等价物的净增加额--144,342,448.22--152,483,470.14
公告日期2026-04-282026-04-212025-10-282025-08-19
审计意见(境内)标准无保留意见
TOP↑